Manufacturing

Oct 04, 2013
By BioPharm International Editors
The sterile injectable manufacturer Ben Venue decides to end production despite efforts to remediate cGMP violations.
Oct 04, 2013
PhRMA report reflects robust R&D in vaccine development.
Oct 02, 2013
By BioPharm International Editors
Fujifilm Diosynth Biotechnologies? new mammalian cell-culture facility uses primarily single-use technologies.
Oct 02, 2013
By BioPharm International Editors
GlaxoSmithKline?s sale of its thrombosis brands is part of a focus on its late-stage pipeline.
Oct 01, 2013
BioPharm International
By BioPharm International Editors
The authors review the angiopoietin pathway as an alternative for safer and more efficacious anti-angiogenic therapeutics.
Oct 01, 2013
BioPharm International
Manufacturing standards are considered key to preventing drug recalls and shortages.
Sep 01, 2013
BioPharm International
By BioPharm International Editors
As the complex requirements of manufacturing biologics are manifold, it is important that biomanufacturing companies adopt quality-by-design principles.
Sep 01, 2013
BioPharm International
Are strategic partnerships in clinical research a model for CMC services?
Sep 01, 2013
BioPharm International
By BioPharm International Editors
Restricted access barrier systems (RABS) maximize product control but minimize operator interaction in aseptic manufacturing.
Sep 01, 2013
BioPharm International
Mike Jenkins, general manager of Catalent Biologics discusses the evolving landscape of the biologics market and hurdles faced in the development and manufacture of these innovative products.
native1_300x100
lorem ipsum